Last reviewed · How we verify
NCT03947853: THETIS
Clinical Study to Evaluate the Predictive Value of the Heart Failure Questionnaire (HF-Q) for the Occurrence of Μajor Αdverse Cardiovascular Events (MACE) in Patients With Symptomatic Heart Failure
trial in Heart Failure. Withdrawn.
31 January 2020
Quick facts
| Lead sponsor | Elpen Pharmaceutical Co. Inc. |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 October 2019 |
| Primary completion | 31 January 2020 |
| Estimated completion | 31 January 2020 |
Conditions studied
- Heart Failure — all drugs for Heart Failure →
- Heart Failure NYHA Class III — all drugs for Heart Failure NYHA Class III →
- Heart Failure NYHA Class II — all drugs for Heart Failure NYHA Class II →
- Heart Failure NYHA Class IV — all drugs for Heart Failure NYHA Class IV →
Sponsor
Elpen Pharmaceutical Co. Inc. — full company profile →
Who can join
Adults 18 to 90, any sex, with Heart Failure or Heart Failure NYHA Class III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiac Heart Failure Questionnaire HF-Q) to assess the severity of the symptoms of Heart Failure. In this study, modified and translated, the "four-point" questionnaire by Severo and his associates - Heart Failure Questionnaire HF-Q, is used. The HF-Q Heart Failure Questionnaire consists of four closed questions: the first with four possible answers and the other three questions with the possibility of three simple-choice answers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03947853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Elpen Pharmaceutical Co. Inc. trials
Trials by the same sponsor.
- NCT07352878 — Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece. · not yet recruiting
- NCT06949956 — Administration of Fingolimod in Greek Patients With Multiple Sclerosis. · not yet recruiting
- NCT06528613 — Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin. · recruiting
- NCT06117722 — TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. · unknown
- NCT05426915 — Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03947853 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elpen Pharmaceutical Co. Inc.
- Last refreshed: 30 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03947853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing